A clinical trial (NCT02640209) evaluated the safety and efficacy of the combination of anti-CD19 CAR T cells with ibrutinib in r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with partial response or stable disease after ibrutinib monotherapy, showing a high rate of sustained responses with the combination therapy [96]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.